2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Robin Kate Kelley: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Nivolumab, Sorafenib - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Phase 2 | Completed | Robin Kate Kelley | 16 | 2018-04-16 | 2025-02-11 |
| Pembrolizumab and GM-CSF in Biliary Cancer Pembrolizumab, Sargramostim - Biliary Cancer | Phase 2 | Completed | Robin Kate Kelley | 42 | 2016-05-06 | 2022-01-25 |
Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1)
Granulocyte-Macrophage Colony-Stimulating Factor (1) · Nivolumab (1) · Sorafenib (1) · pembrolizumab (1) · sargramostim (1)
United States (2)
R. Kate Kelley, M.D. (1) · Robin K. Kelley, MD (1)
R03CA212877 (1)